ArticleInflammopharmacology2026
α-Pinene alleviates inflammatory responses and oxidative stress in freund's complete adjuvant induced arthritic rat model and associated risk factors of atherosclerosis.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unraveling the Anti-Arthritic Potential of Bioactive Compounds FromFood science & nutrition · 2026Article
- Sanguinarine ameliorates rheumatoid arthritis by activating the Hippo-YAP/TAZ pathway to induce apoptosis and suppress inflammation in fibroblast-like synoviocytes.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arthritis is characterized by joint inflammation that can lead to severe bone erosions and affects 0.1 to 2.0% of people globally. People with RA are 1.5 times more likely to develop CVDs including atherosclerosis. The goal of the current investigation was to determine the effect of α-Pinene in FCA induced RA and associated atherosclerosis in rat model. In an experimental model of 23 days, 0.15mL FCA was administered for RA induction. Treatment drug α-Pinene was administered in different doses (25mg/kg, 50mg/kg and 100mg/kg) and a standard methotrexate (0.75mg/kg). Parameters like body weight, paw thickness, arthritic scoring, joint stiffness, hematological, serological, biochemical and inflammatory markers (DDAH, CST, TNF-α, IL-6, IL-1β) were analyzed. The results showed that treatment with α-Pinene, especially its combination with MSTD significantly (p < 0.001) ameliorates body weight, paw thickness, arthritic scoring, joint stiffness, hematological, lipid profile, and restored the endogenous anti-oxidant (SOD, CAT, GSH, MDA and Nitrite) activities. α-PNHD + MSTD also significantly (p < 0.001) reduced ADMA, pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and increased DDAH or CST expression. Histopathological analysis showed that α-PNHD + MSTD significantly (p < 0.001) alleviated bone and cartilage erosion, pannus formation, synovial hyperplasia and vascular congestion. Thus, α-Pinene's anti-inflammatory and anti-oxidant properties suggests its therapeutic effectiveness in RA and its associated risk of atherosclerosis. Its combination with MSTD suggests promising therapeutic profile and warrants for further research and development in the field of rheumatology.
Indexed as
Identifiers
41888386What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.